Goel Anurag, Barnes Cara J, Osman Hisham, Verma Ashwin
Department of Gastroenterology, Calderdale Royal Hospital, Halifax, UK.
Eur J Gastroenterol Hepatol. 2007 Jan;19(1):51-6. doi: 10.1097/MEG.0b013e3280120eb5.
Anticoagulated patients who need to undergo endoscopy present unique challenges to the gastroenterologist. The continuation of anticoagulant therapy increases the risk of haemorrhagic complications of gastrointestinal endoscopy. Reversing the anticoagulation increases the risk of thromboembolism. In our experience in various endoscopy units, there are variable policies on the management of anticoagulated patients undergoing gastrointestinal endoscopy.
To study the current practice, survey questionnaires were sent to 2320 doctors, working in 231 hospitals across the United Kingdom.
Responses were obtained from 219 hospitals (94.8%), but only from 434 doctors (18.7%). The results show 40.8% endoscopists continued the patients on warfarin when performing a planned upper gastrointestinal endoscopy, whereas 26% stopped it; 33.2% gave varying reports, that is, they used their own judgement according to the disease for which the anticoagulant was being given. For planned lower gastrointestinal endoscopy, 48.7% doctors preferred to stop warfarin; 53.3% of the endoscopists stated that they have a policy in place at their hospital for both upper and lower gastrointestinal endoscopy in anticoagulated patients; 5.5% had a policy for upper gastrointestinal endoscopy only and 6.2% for lower gastrointestinal endoscopy only. Thirty-five per cent doctors reported that they did not have any standard policy. We compared the responses from within a hospital to see whether the doctors were uniformly aware of an existing policy in their hospital. For upper gastrointestinal endoscopy, the responses were the same (either yes or no) by 51% of the doctors, whereas they were different by 49%. For lower gastrointestinal endoscopies, the same response was given by 49% of the doctors, whereas 51% gave different answers. The poor response rate from the doctors, however, makes firm interpretation of the data difficult.
A wide variation in practice is seen across the country. A robust national guideline to streamline the endoscopy practice in anticoagulated patients is needed.
需要接受内镜检查的抗凝患者给胃肠病学家带来了独特的挑战。继续抗凝治疗会增加胃肠内镜检查出血并发症的风险。逆转抗凝会增加血栓栓塞的风险。根据我们在各个内镜检查科室的经验,对于接受胃肠内镜检查的抗凝患者的管理存在不同的政策。
为研究当前的做法,向英国231家医院的2320名医生发送了调查问卷。
收到了来自219家医院(94.8%)的回复,但仅来自434名医生(18.7%)。结果显示,40.8%的内镜医师在进行计划性上消化道内镜检查时让患者继续服用华法林,而26%的医师则停用;33.2%给出了不同的报告,即他们根据使用抗凝剂治疗的疾病自行判断。对于计划性下消化道内镜检查,48.7%的医生倾向于停用华法林;53.3%的内镜医师表示他们所在医院针对抗凝患者的上消化道和下消化道内镜检查都有相关政策;5.5%仅有上消化道内镜检查的政策,6.2%仅有下消化道内镜检查的政策。35%的医生报告称他们没有任何标准政策。我们比较了同一家医院内医生的回复,以查看医生们是否一致知晓他们医院现有的政策。对于上消化道内镜检查,51%的医生回复相同(是或否),而49%的医生回复不同。对于下消化道内镜检查,49%的医生给出相同回复,而51%的医生给出不同答案。然而,医生的低回复率使得对数据进行确切解读变得困难。
全国各地的做法差异很大。需要一个强有力的国家指南来规范抗凝患者的内镜检查操作。